United Kingdom· GB-APID-13667811000001109
Tyverb 250mg tablets
A lapatinib product containing lapatinib, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lapatinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EH01 (lapatinib), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 6 of them publish a price we can compare per daily dose
Lapatinib · ATC L01EH01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of lapatinib costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lapatinib · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$101.12
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lapatinib
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01EH01
- ATC class
- Lapatinib
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 5
- gtin5000123112487
- gtin5000123113682
- gtin7612797331217
- gtin5000123113965
- gtin7612797333730
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
675 interactions on record for lapatinib.
Graded by severity as the source publishes them — 124 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lapatinib · interactions on record
675 records
- 124 severe
- 537 moderate
- 14 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LoperamideA07DA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lapatinib in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaTYKERBNOVARTIS PHARMACEUTICALS CANADA INC
- SpainLAPATINIB STADA 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGLaboratorio Stada S.L.
- SwitzerlandTyverb, FilmtablettenNovartis Pharma Schweiz AG
- GermanyLapatinib AlAliud Pharma Gmbh
- PolandBrastibSTADA Arzneimittel AG
- SwedenLapatinib Newbury 250 mg Filmdragerad tablettNewbury Pharmaceuticals AB
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Cyprus · Laprem
- Germany · Lapatinib Al, Lapatinib Stada
- Denmark · Lapatinib Newbury
- Spain · Lapatinib Stada
- France · Lapatinib Pharos
- Iceland · Lapatinib Newbury, Tyverb
- Liechtenstein · Tyverb
- Malta · Lapatinib Pharos
- Netherlands · Brastib, Lapatinib Pharos
- Norway · Tyverb
- Poland · Brastib
- Romania · Lapatinib Stada
- Sweden · Lapatinib Newbury
- Slovakia · Lapatinib Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6f04e5c-fc35-4ab0-ba07-973136bfb73b GET /v1/drugs/b6f04e5c-fc35-4ab0-ba07-973136bfb73b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "13667811000001109",
"desc": "Tyverb 250mg tablets (Novartis Pharmaceuticals UK Ltd)",
"form": "Oral tablet",
"vpid": "39697211000001105",
"source": "dmd",
"vtm_id": "776478009",
"strength": "250 mg",
"substance": "Lapatinib",
"ingredient": "Lapatinib ditosylate monohydrate",
"supplier_code": "2920101000001102"
}See everything about lapatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.